Adial Pharmaceuticals Inc. Stock News

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therap

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther

Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of

Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phas

Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinica

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing

New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adia

CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on develop

Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular gene

Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member Highly Experienced Pharma Commercial and Bus

CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve

CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve

Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Mill

CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve